|
Jan 1
|
Jim Cramer’s Take on Vertex Pharmaceuticals (VRTX): Bold Predictions for the Future
|
|
Dec 31
|
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
|
|
Dec 31
|
Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago are up 79%
|
|
Dec 30
|
Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?
|
|
Oct 4
|
Insider Trades: How to Find the Top Stocks
|
|
Oct 4
|
DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million
|
|
Oct 4
|
3 Top Stocks That Could Still Rocket Higher in 2024
|
|
Oct 4
|
2 Superior Growth Stocks That Are Screaming Buys Right Now
|
|
Oct 3
|
Reasons that Lifted Vertex Pharmaceuticals Incorporated (VRTX) in Q2
|
|
Oct 1
|
5 FDA decisions to watch in the fourth quarter
|
|
Sep 30
|
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Sep 27
|
Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data
|
|
Sep 26
|
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
|
|
Sep 26
|
Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
|
|
Sep 26
|
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
|
|
Sep 25
|
Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Sep 25
|
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
|
|
Sep 5
|
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
|
|
Sep 2
|
Is DexCom a Millionaire-Maker Stock?
|
|
Aug 31
|
3 No-Brainer Stocks to Buy in September
|